The injection of Ghrelin (OXE-103) improves subacute concussion symptom burden and quality of life

Written By Lindsey McClelland

A Ph2a Concussion study of Oxeia Biopharmaceutical’s drug, OXE103, showed strong potential as an effective concussion treatment. Dr. Michael Rippee of KUMC Medical Center presented the findings during the ACRM Conference on 10/31

Lindsey McClelland
Previous

CONCUSSION DRUG STUDY SHOWS POSITIVE EARLY RESULTS
Next

A tough puzzle: complexity slows drug development for concussions